European shares dip as higher crude revives inflation worries; Novartis drags
European shares dip as higher crude revives inflation worries; Novartis drags For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
Sept 8 (Reuters) - European shares edged lower on Tuesday as rising oil prices fuelled inflation worries and supply concerns over a prolonged Middle East conflict, while Novartis came under pressure after reporting its second drug development setback.
The pan-European STOXX 600 .STOXX was down 0.2% at 648.41 points by 0705 GMT. Germany's DAX .GDAXI shed 0.3%, London's FTSE .FTSE was flat and France's CAC 40 .FCHI slipped 0.4%, following a relatively subdued session on Monday due to a U.S. public holiday.
Novartis NOVN.S tumbled 8.8% after the Swiss drugmaker said late-stage testing of the del-desiran drug for myotonic dystrophy failed to meet its primary endpoint. The disappointment follows another closely watched setback announced on Monday, when its experimental cholesterol drug pelacarsen failed to deliver positive results in a late-stage trial.
Oil prices climbed, with Brent crude futures LCOc1 trading at $98.5 per barrel after Iran threatened to retaliate against any new attacks by targeting energy infrastructure across the Gulf, including U.S. oil and gas interests. O/R
Among individual movers, Sandoz SDZ.S added 2.9% after the Swiss pharma firm said it aims to more than double net sales from 2025 to 2035.
Poste Italiane PST.MI sweetened its takeover offer for Telecom Italia TLIT.MI as it seeks to secure control of Italy's former phone monopoly. Shares of Poste were down 0.2%.
(Reporting by Sudeshna Ghoshal in Bengaluru; Editing by Sonia Cheema)
Recent news on Novartis AG
See all newsNovartis AG expected to post earnings of $2.27 a share - Earnings Preview
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination (updated)
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
Brief: Novartis Receives European Commission Approval For Cosentyx
Insight: How cheap Chinese antibiotics threaten Europe's last major penicillin plant